1. PARP inhibitors: a tsunami of indications in different malignancies
- Author
-
Roland Eid, Fady Gh Haddad, Marie Christelle W Saadé, Gaëlle Haddad, and Hampig Raphael Kourie
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,DNA Repair ,Poly ADP ribose polymerase ,Poly(ADP-ribose) Polymerase Inhibitors ,Olaparib ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Neoplasms ,Internal medicine ,Genetics ,Humans ,Medicine ,Talazoparib ,Precision Medicine ,Rucaparib ,Drug Approval ,BRCA2 Protein ,Pharmacology ,Clinical Trials as Topic ,BRCA1 Protein ,business.industry ,Cancer ,medicine.disease ,Precision medicine ,Survival Analysis ,030104 developmental biology ,Positive response ,chemistry ,030220 oncology & carcinogenesis ,Mutation ,Molecular Medicine ,business ,Ovarian cancer - Abstract
The evolution of precision medicine in the field of oncology has led to a radical change in the course of malignancies. PARP inhibitors are drugs that block the activity of the PARP enzyme responsible for base excision repair and have shown significant positive response when used for tumors lacking homologous recombination, namely high efficacy among BRCA-mutated tumors. Since 2014, when olaparib received an accelerated US FDA approval in ovarian cancer, we witnessed many other FDA approvals for olaparib, rucaparib, niraparib and talazoparib. Additionally, many Phase I, II and III trials were published presenting revolutionizing results. Other ongoing trials combined PARP inhibitors with checkpoint inhibitors. We aimed in this review to state the FDA approvals for PARP inhibitors in breast, ovarian, fallopian tube and primary peritoneal cancers, report the major published trials in high impact medical journals, and mention the ongoing trials combining these drugs with checkpoint inhibitors.
- Published
- 2020